Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 102,057 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. purchased 102,057 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was purchased at an average price of $3.45 per share, with a total value of $352,096.65. Following the purchase, the insider directly owned 12,033,896 shares of the company’s stock, valued at $41,516,941.20. The trade was a 0.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The stock was purchased at an average cost of $3.88 per share, for a total transaction of $157,877.20.
• On Friday, April 17th, Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock. The stock was purchased at an average price of $3.57 per share, for a total transaction of $143,206.98.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The shares were purchased at an average cost of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Trading Up 3.9%

Shares of IMDX stock opened at $3.99 on Tuesday. The firm has a market capitalization of $128.36 million, a P/E ratio of -2.46 and a beta of 1.52. The stock’s fifty day moving average price is $4.57. Oncocyte Corp has a 12 month low of $2.33 and a 12 month high of $8.51.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $1.14 million during the quarter.

Analysts Set New Price Targets

IMDX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Finally, Lake Street Capital increased their target price on shares of Oncocyte from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.